Psychopharmacology

, Volume 212, Issue 4, pp 663–674

Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination

  • Petra S. van Nieuwenhuijzen
  • Leonora E. Long
  • Glenn E. Hunt
  • Jonathon C. Arnold
  • Iain S. McGregor
original investigation

Abstract

Rationale

There has been little investigation of the possible lasting adverse effects of γ-hydroxybutyrate (GHB).

Objectives

This study aims to study whether GHB produces residual adverse effects on memory and social behaviour in rats and lasting changes in brain monoamines and oxytocin-related gene expression.

Methods

Rats received daily intraperitoneal injections of GHB (500 mg/kg), methylenedioxymethamphetamine (MDMA; 5 mg/kg) or their combination (GHB/MDMA) over ten consecutive days. Locomotor activity and body weight were assessed during the dosing period and withdrawal-related anxiety was assessed 24 h after drug cessation. After a washout of 4 weeks, rats were tested on the emergence, social interaction, and object recognition tasks over a 2-week period. Monoamine levels in cortex and striatum, and hypothalamic oxytocin and oxytocin receptor mRNA, were then assessed.

Results

MDMA and GHB/MDMA caused modest sensitization of locomotor activity over time, while sedative effects of GHB diminished with repeated exposure. GHB-treated rats showed reduced social interaction 24 h after the final dose, indicating GHB withdrawal-induced anxiety. All drug-treated groups displayed residual deficits in social interaction and object recognition. No changes in monoamine levels were detected 8 weeks post-drug. However, MDMA pre-exposure increased hypothalamic oxytocin mRNA while GHB pre-exposure upregulated oxytocin receptor mRNA. GHB/MDMA pre-exposure caused intermediate changes in both of these measures.

Conclusions

GHB treatment caused residual impairments in memory and social behaviour and increases in anxiety, paralleling the lasting adverse effects of MDMA. Both drugs caused lasting neuroadaptations in brain oxytocin systems and this may be related to the long-term social interaction deficiencies caused by both drugs.

Keywords

GHB MDMA Oxytocin Memory Anxiety Social behaviour 5-HT 

References

  1. Able JA, Gudelsky GA, Vorhees CV, Williams MT (2006) 3, 4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory. Biol Psychiatry 59:1219–1226CrossRefPubMedGoogle Scholar
  2. Andriamampandry C, Taleb O, Viry S, Muller C, Humbert JP, Gobaille S, Aunis D, Maitre M (2003) Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J 17:1691–1693PubMedGoogle Scholar
  3. Bania TC, Ashar T, Press G, Carey PM (2003) Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model. Acad Emerg Med 10:697–704CrossRefPubMedGoogle Scholar
  4. Baumann MH, Wang X, Rothman RB (2007) 3, 4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189:407–424CrossRefGoogle Scholar
  5. Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006) Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 31:2537–2551CrossRefPubMedGoogle Scholar
  6. Clemens KJ, Cornish JL, Hunt GE, McGregor IS (2007) Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend 86:183–190CrossRefPubMedGoogle Scholar
  7. Colussi-Mas J, Schenk S (2008) Acute and sensitized response to 3, 4-methylenedioxymethamphetamine in rats: different behavioral profiles reflected in different patterns of Fos expression. Eur J Neurosci 28:1895–1910CrossRefPubMedGoogle Scholar
  8. Conductier G, Crosson C, Hen R, Bockaert J, Compan V (2005) 3, 4-N-methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS102221. Neuropsychopharmacology 30:1056–1063CrossRefPubMedGoogle Scholar
  9. Cruz HG, Ivanova T, Lunn ML, Stoffel M, Slesinger PA, Luscher C (2004) Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci 7:153–159CrossRefPubMedGoogle Scholar
  10. Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, van Gerven JM, Buitelaar JK, Verkes RJ (2009) Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3, 4-methylenedioxymethamphetamine) administration. Soc Neurosci 4:359–366CrossRefPubMedGoogle Scholar
  11. Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31:47–59CrossRefPubMedGoogle Scholar
  12. File SE, Mabbutt PS, Andrews N (1991) Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen. Psychopharmacology (Berl) 104:62–66CrossRefGoogle Scholar
  13. Fone KC, Beckett SR, Topham IA, Swettenham J, Ball M, Maddocks L (2002) Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl) 159:437–444CrossRefGoogle Scholar
  14. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ (2002) The effect of 3, 4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135:649–656CrossRefPubMedGoogle Scholar
  15. Frenzilli G, Ferrucci M, Giorgi FS, Blandini F, Nigro M, Ruggieri S, Murri L, Paparelli A, Fornai F (2007) DNA fragmentation and oxidative stress in the hippocampal formation: a bridge between 3, 4-methylenedioxymethamphetamine (ecstasy) intake and long-lasting behavioral alterations. Behav Pharmacol 18:471–481CrossRefPubMedGoogle Scholar
  16. Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF (2004) The Xyrem risk management program. Drug Saf 27:293–306CrossRefPubMedGoogle Scholar
  17. Geldenhuys FG, Sonnendecker EW, De Klrk MC (1968) Experience with sodium-gamma-4-hydroxybutyric acid (gamma-OH) in obstetrics. J Obstet Gynaecol Br Commonw 75:405–413PubMedGoogle Scholar
  18. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J (2003) Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27:819–827CrossRefPubMedGoogle Scholar
  19. Green A, Marsden C, Fone K (2008) MDMA as a clinical tool: a note of caution. A response to Sessa and Nutt. J Psychopharmacol 22:929–931CrossRefPubMedGoogle Scholar
  20. Harkin A, Connor TJ, Mulrooney J, Kelly JP, Leonard BE (2001) Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sci 68:1367–1382CrossRefPubMedGoogle Scholar
  21. Husain AM, Ristanovic RK, Bogan RK (2009) Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med 10:661–663CrossRefPubMedGoogle Scholar
  22. Itzhak Y, Ali SF (2002) Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Ann NY Acad Sci 965:451–460CrossRefPubMedGoogle Scholar
  23. Jean A, Conductier G, Manrique C, Bouras C, Berta P, Hen R, Charnay Y, Bockaert J, Compan V (2007) Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens. Proc Natl Acad Sci USA 104:16335–16340CrossRefPubMedGoogle Scholar
  24. Kaupmann K, Cryan JF, Wellendorph P, Mombereau C, Sansig G, Klebs K, Schmutz M, Froestl W, van der Putten H, Mosbacher J, Brauner-Osborne H, Waldmeier P, Bettler B (2003) Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci 18:2722–2730CrossRefPubMedGoogle Scholar
  25. Knapp DJ, Overstreet DH, Breese GR (2007) Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res 31:582–595CrossRefPubMedGoogle Scholar
  26. Kovacs GL, Sarnyai Z, Szabo G (1998) Oxytocin and addiction: a review. Psychoneuroendocrinology 23:945–962CrossRefPubMedGoogle Scholar
  27. Kueh D, Iwamoto K, Poling A, Baker LE (2008) Effects of gamma-hydroxybutyrate (GHB) and its metabolic precursors on delayed-matching-to-position performance in rats. Pharmacol Biochem Behav 89:179–187CrossRefPubMedGoogle Scholar
  28. Lee SJ, Levounis P (2008) Gamma hydroxybutyrate: an ethnographic study of recreational use and abuse. J Psychoactive Drugs 40:245–253PubMedGoogle Scholar
  29. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI (2005) Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30:1883–1894CrossRefPubMedGoogle Scholar
  30. LeTourneau JL, Hagg DS, Smith SM (2008) Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 8:430–433CrossRefPubMedGoogle Scholar
  31. Lipschitz DL, Crowley WR, Armstrong WE, Bealer SL (2005) Neurochemical bases of plasticity in the magnocellular oxytocin system during gestation. Exp Neurol 196:210–223CrossRefPubMedGoogle Scholar
  32. Ludwig V, Mihov Y, Schwarting RK (2008) Behavioral and neurochemical consequences of multiple MDMA administrations in the rat: role of individual differences in anxiety-related behavior. Behav Brain Res 189:52–64CrossRefPubMedGoogle Scholar
  33. McElroy SL, Guerdjikova AI, Winstanley EL, O’Melia AM, Mori N, Keck PE, Jr., Hudson JI (2010) Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study. Int J Eat Disord (in press)Google Scholar
  34. McGregor IS, Clemens KJ, Van der Plasse G, Li KM, Hunt GE, Chen F, Lawrence AJ (2003a) Increased anxiety 3 months after brief exposure to MDMA (“Ecstasy”) in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28:1472–1484CrossRefPubMedGoogle Scholar
  35. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM, Cornish JL, Hunt GE (2003b) Increased anxiety and “depressive” symptoms months after MDMA (“ecstasy”) in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology (Berl) 168:465–474CrossRefGoogle Scholar
  36. McGregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? Br J Pharmacol 154:358–368CrossRefPubMedGoogle Scholar
  37. McMurray MS, Williams SK, Jarrett TM, Cox ET, Fay EE, Overstreet DH, Walker CH, Johns JM (2008) Gestational ethanol and nicotine exposure: effects on maternal behavior, oxytocin, and offspring ethanol intake in the rat. Neurotoxicol Teratol 30:475–486CrossRefPubMedGoogle Scholar
  38. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS (2001) Increased anxiety and impaired memory in rats 3 months after administration of 3, 4-methylenedioxymethamphetamine (“ecstasy”). Eur J Pharmacol 433:91–99CrossRefPubMedGoogle Scholar
  39. Navarro JF, Pedraza C, Gonzalez F (2007) Acute and subchronic effects of gamma-hydroxybutyrate on isolation-induced aggression in male mice. Meth Find Exp Clin Pharmacol 29:379–382CrossRefGoogle Scholar
  40. Navarro JF, Davila G, Pedraza C, Arias JL (2008) Anxiogenic-like effects of gamma-hydroxybutyric acid (GHB) in mice tested in the light-dark box. Psicothema 20:460–464PubMedGoogle Scholar
  41. Neumann ID (2008) Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J Neuroendocrinol 20:858–865CrossRefPubMedGoogle Scholar
  42. Nutt D (2009) Equasy—an overlooked addiction with implications for the current debate on drug harms. J Psychopharmacol 23:3–5CrossRefPubMedGoogle Scholar
  43. O’Shea E, Granados R, Esteban B, Colado MI, Green AR (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (‘ecstasy’). Neuropharmacology 37:919–926CrossRefPubMedGoogle Scholar
  44. O’Shea E, Orio L, Escobedo I, Sanchez V, Camarero J, Green AR, Colado MI (2006) MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 148:778–785CrossRefPubMedGoogle Scholar
  45. Pedraza C, Garcia FB, Navarro JF (2009) Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats. Int J Neuropsychopharmacol 12:1165–1177Google Scholar
  46. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36CrossRefPubMedGoogle Scholar
  47. Piper BJ, Fraiman JB, Owens CB, Ali SF, Meyer JS (2008) Dissociation of the neurochemical and behavioral toxicology of MDMA (‘Ecstasy’) by citalopram. Neuropsychopharmacology 33:1192–1205CrossRefPubMedGoogle Scholar
  48. Queva C, Bremner-Danielsen M, Edlund A, Ekstrand AJ, Elg S, Erickson S, Johansson T, Lehmann A, Mattsson JP (2003) Effects of GABA agonists on body temperature regulation in GABA(B(1))−/− mice. Br J Pharmacol 140:315–322CrossRefPubMedGoogle Scholar
  49. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, Dawson B, Mallet PE, Kashem MA, Matsuda-Matsumoto H, Iwazaki T, McGregor IS (2008) Adolescent rats find repeated delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33:1113–1126CrossRefPubMedGoogle Scholar
  50. Robinson TE, Berridge KC (2003) Addiction. Annu Rev Psychol 54:25–53CrossRefPubMedGoogle Scholar
  51. Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, Zawada A, Somerville M (2009) The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 13(iii–iv, ix–xii):1–315Google Scholar
  52. Sarnyai Z, Biro E, Babarczy E, Vecsernyes M, Laczi F, Szabo G, Krivan M, Kovacs GL, Telegdy G (1992) Oxytocin modulates behavioural adaptation to repeated treatment with cocaine in rats. Neuropharmacology 31:593–598CrossRefPubMedGoogle Scholar
  53. Sgaravatti AM, Sgarbi MB, Testa CG, Durigon K, Pederzolli CD, Prestes CC, Wyse AT, Wannmacher CM, Wajner M, Dutra-Filho CS (2007) Gamma-hydroxybutyric acid induces oxidative stress in cerebral cortex of young rats. Neurochem Int 50:564–570CrossRefPubMedGoogle Scholar
  54. Sgaravatti AM, Magnusson AS, Oliveira AS, Mescka CP, Zanin F, Sgarbi MB, Pederzolli CD, Wyse AT, Wannmacher CM, Wajner M, Dutra-Filho CS (2009) Effects of 1, 4-butanediol administration on oxidative stress in rat brain: study of the neurotoxicity of gamma-hydroxybutyric acid in vivo. Metab Brain Dis 24:271–282CrossRefPubMedGoogle Scholar
  55. Silva SM, Madeira MD, Ruela C, Paula-Barbosa MM (2002) Prolonged alcohol intake leads to irreversible loss of vasopressin and oxytocin neurons in the paraventricular nucleus of the hypothalamus. Brain Res 925:76–88CrossRefPubMedGoogle Scholar
  56. Sircar R, Basak A, Sircar D (2008) Gamma-hydroxybutyric acid-induced cognitive deficits in the female adolescent rat. Ann NY Acad Sci 1139:386–389CrossRefPubMedGoogle Scholar
  57. Sivukhina EV, Dolzhikov AA, Morozov Iu E, Jirikowski GF, Grinevich V (2006) Effects of chronic alcoholic disease on magnocellular and parvocellular hypothalamic neurons in men. Horm Metab Res 38:382–390CrossRefPubMedGoogle Scholar
  58. Stone DM, Merchant KM, Hanson GR, Gibb JW (1987) Immediate and long-term effects of 3, 4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677–1683CrossRefPubMedGoogle Scholar
  59. Sumnall HR, Woolfall K, Edwards S, Cole JC, Beynon CM (2008) Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend 92:286–290CrossRefPubMedGoogle Scholar
  60. Theodosis DT, Schachner M, Neumann ID (2004) Oxytocin neuron activation in NCAM-deficient mice: anatomical and functional consequences. Eur J Neurosci 20:3270–3280CrossRefPubMedGoogle Scholar
  61. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3, 4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience 146:509–514CrossRefPubMedGoogle Scholar
  62. Thompson MR, Hunt GE, McGregor IS (2009) Neural correlates of MDMA (“Ecstasy”)-induced social interaction in rats. Soc Neurosci 4:60–72CrossRefPubMedGoogle Scholar
  63. Uys JD, Niesink RJ (2005) Pharmacological aspects of the combined use of 3, 4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature. Drug Alcohol Rev 24:359–368CrossRefPubMedGoogle Scholar
  64. van Nieuwenhuijzen PS, McGregor IS (2009) Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry. Drug Alcohol Depend 103:137–147CrossRefPubMedGoogle Scholar
  65. van Nieuwenhuijzen PS, Li K, Hunt GE, McGregor IS (2009a) Weekly gamma-hydroxybutyrate (GHB) exposure sensitizes locomotor hyperactivity to low dose 3, 4-methylenedioxymethamphetamine (MDMA) in rats. Neuropsychobiology 60:195–203CrossRefPubMedGoogle Scholar
  66. van Nieuwenhuijzen PS, McGregor IS, Hunt GE (2009b) The distribution of gamma-hydroxybutyrate-induced Fos expression in rat brain: comparison with baclofen. Neuroscience 158:441–455CrossRefPubMedGoogle Scholar
  67. van Nieuwenhuijzen PS, Kashem MA, Matsumoto I, Hunt GE, McGregor IS (2010) A long hangover from party drugs: residual proteomic changes in the hippocampus of rats 8 weeks after gamma-hydroxybutyrate (GHB), 3, 4-methylenedioxymethamphetamine (MDMA) or their combination. Neurochem Int 56:871–877CrossRefPubMedGoogle Scholar
  68. Weerts EM, Goodwin AK, Griffiths RR, Brown PR, Froestl W, Jakobs C, Gibson KM (2005) Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. Psychopharmacology (Berl) 179:678–687CrossRefGoogle Scholar
  69. Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, Aitchison KJ (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 20:400–410CrossRefPubMedGoogle Scholar
  70. You ZD, Li JH, Song CY, Wang CH, Lu CL (2000) Chronic morphine treatment inhibits oxytocin synthesis in rats. NeuroReport 11:3113–3116CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Petra S. van Nieuwenhuijzen
    • 1
  • Leonora E. Long
    • 1
  • Glenn E. Hunt
    • 2
  • Jonathon C. Arnold
    • 3
  • Iain S. McGregor
    • 1
  1. 1.School of PsychologyUniversity of SydneySydneyAustralia
  2. 2.Discipline of Psychological Medicine, Concord HospitalUniversity of SydneySydneyAustralia
  3. 3.School of Medical Science (Pharmacology)University of SydneySydneyAustralia

Personalised recommendations